NVS•benzinga•
Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims
Summary
A federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 14, 2022 by benzinga